iBio Commercial Vaccine IP Expanded by New iBioModulator™ Patent Allowance
NEWARK, Del., Aug. 5, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) announced today that the US Patent and Trademark Office has allowed patent application 13/445,492 entitled "Recombinant Carrier Molecule for Expression, Delivery, and Purification of Target Polypeptides." The fundamental composition of matter and method claims allowed grant important exclusivity over new, modified carrier molecules derived from iBio's proprietary iBioModulator system and their use with one or more target proteins or antigens. The new carriers provide new capabilities to create high-performance vaccine candidates for difficult disease targets. The invention was developed by scientists at the Fraunhofer USA Center for Molecular Biotechnology, iBio's research collaborator.
The iBioModulator platform has been shown to significantly modify the immune response to a vaccine in two important ways. It increases the strength of the initial immune response to a vaccine antigen (as measured by antibody titer). It also extends the duration of the immune response, thus lowering vaccine antigen requirements or enabling fewer doses to establish prolonged immunity. Generating a stronger immune response and longer-term protection without booster inoculations adds significant value to a vaccine by reducing the overall costs and logistical difficulties of its use while effectively reaching a higher proportion of the target population.
iBio uses the iBioModulator platform, including the technology covered by this new patent, for the biopharmaceutical products it develops with its proprietary iBioLaunch plant-based protein expression system. iBio also offers the benefits of the iBioModulator platform through licenses to product developers who use the iBioLaunch system or other protein expression systems.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. Additionally, iBio is developing select product candidates that have been derived from the iBioLaunch platform. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and is designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
SOURCE iBio, Inc.
More by this Source
iBio Resolves NYSE MKT Listing Standards Deficiency
Oct 28, 2013, 08:10 ET
iBio, Inc. Announces Temporary Reduction in Exercise Price of Certain Warrants
Oct 15, 2013, 18:41 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.